Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsTan, Wan C
Vollmer, William M
Mannino, David M
Burney, Peter G J
Buist, A Sonia
MetadataShow full item record
CitationThorax 2012, 67(8):718-26
ÚtdrátturCriteria for a clinically significant bronchodilator response (BDR) are mainly based on studies in patients with obstructive lung diseases. Little is known about the BDR in healthy general populations, and even less about the worldwide patterns. 10 360 adults aged 40 years and older from 14 countries in North America, Europe, Africa and Asia participated in the Burden of Obstructive Lung Disease study. Spirometry was used before and after an inhaled bronchodilator to determine the distribution of the BDR in population-based samples of healthy non-smokers and individuals with airflow obstruction. In 3922 healthy never smokers, the weighted pooled estimate of the 95th percentiles (95% CI) for bronchodilator response were 284 ml (263 to 305) absolute change in forced expiratory volume in 1 s from baseline (ΔFEV(1)); 12.0% (11.2% to 12.8%) change relative to initial value (%ΔFEV(1i)); and 10.0% (9.5% to 10.5%) change relative to predicted value (%ΔFEV(1p)). The corresponding mean changes in forced vital capacity (FVC) were 322 ml (271 to 373) absolute change from baseline (ΔFVC); 10.5% (8.9% to 12.0%) change relative to initial value (ΔFVC(i)); and 9.2% (7.9% to 10.5%) change relative to predicted value (ΔFVC(p)). The proportion who exceeded the above threshold values in the subgroup with spirometrically defined Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 and higher (FEV(1)/FVC <0.7 and FEV(1)% predicted <80%) were 11.1%, 30.8% and 12.9% respectively for the FEV(1)-based thresholds and 22.6%, 28.6% and 22.1% respectively for the FVC-based thresholds. The results provide reference values for bronchodilator responses worldwide that confirm guideline estimates for a clinically significant level of BDR in bronchodilator testing.
Lu00FDsingTo access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to Thorax
- Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010.
- Authors: Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B
- Issue date: 2013 Oct 9
- Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD.
- Authors: Schermer T, Heijdra Y, Zadel S, van den Bemt L, Boonman-de Winter L, Dekhuijzen R, Smeele I
- Issue date: 2007 Jun
- The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD.
- Authors: Ben Saad H, Préfaut C, Tabka Z, Zbidi A, Hayot M
- Issue date: 2008 Oct
- Bronchodilator Response in FVC Is Larger and More Relevant Than in FEV<sub>1</sub> in Severe Airflow Obstruction.
- Authors: Quanjer PH, Ruppel GL, Langhammer A, Krishna A, Mertens F, Johannessen A, Menezes AMB, Wehrmeister FC, Perez-Padilla R, Swanney MP, Tan WC, Bourbeau J
- Issue date: 2017 May
- Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease.
- Authors: Albert P, Agusti A, Edwards L, Tal-Singer R, Yates J, Bakke P, Celli BR, Coxson HO, Crim C, Lomas DA, Macnee W, Miller B, Rennard S, Silverman EK, Vestbo J, Wouters E, Calverley P
- Issue date: 2012 Aug